The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global male infertility market size reached US$ 3.55 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.97 Billion by 2027, exhibiting a growth rate (CAGR) of 5.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Male infertility is a disease of the reproductive system that lowers the chance of the affected individual to impregnate a fertile woman. Genetic defects, undescended testicles, sperm illnesses, injuries, lifestyle choices, diabetes, or infections, such as chlamydia, gonorrhea, mumps, or HIV, are some factors that may contribute to male infertility. It can also arise due to abnormal sperm function, blockages, and low sperm production that prevents the delivery of sperm. Male infertility treatment includes hormone therapy, vasoepididymostomy, and assisted reproductive technology (ART) procedures, such as in vitro fertilization (IVF) and varicocele surgery. These procedures help enhance the reproductive health of males, restore testosterone levels, and improve the quality of sperm to enable pregnancy.
Changing lifestyles, delayed pregnancies, and aging are among the key factors driving the market growth. In line with this, the rising incidences of chronic diseases, such as diabetes, obesity, and hypertension, due to sedentary lifestyles and lack of physical activities are favoring the market growth. Moreover, the widespread adoption of deoxyribonucleic acid (DNA) fragmentation techniques and computer-assisted semen analysis to diagnose hypospermia, measure semen volume, and determine male infertility is acting as another growth-inducing factor. Apart from this, the increasing demand for ART procedures, such as IVF, that involve the utilization of previously frozen sperms is providing an impetus to the market growth. Additionally, the growing availability of numerous infertility treatment drugs, procedures, and devices is facilitating the market growth. Besides this, rising workload and the accompanying stress, along with unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, leading to infertility issues among males, are propelling the market growth. Furthermore, the implementation of various government initiatives toward improving reimbursement scenarios for infertility-related treatments and enhance the safety of patient data is positively influencing the market growth. Other factors, including extensive research and development (R&D) activities, rising expenditure capacities of consumers, and growing awareness among individuals about increasing accessibility to improved healthcare facilities, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global male infertility market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on test type, treatment, distribution channel and end user.
Breakup by Test Type:
Breakup by Treatment:
Breakup by Distribution Channel:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Andrology Solutions, CinnaGen Co., Halotech DNA, SCSA Diagnostics Inc., Vitrolife, Zydus Lifesciences Limited, Intas Pharmaceuticals Ltd. and Endo International plc.
|Base Year of the Analysis||2021|
|Segment Coverage||Test Type, Treatment, Distribution Channel, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Andrology Solutions, CinnaGen Co., Halotech DNA, SCSA Diagnostics Inc., Vitrolife, Zydus Lifesciences Limited, Intas Pharmaceuticals Ltd. and Endo International plc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at